DK3336197T3 - Epigenetiske markører og relaterede fremgangsmåder og midler til detektion og behandling af ovariekræft - Google Patents
Epigenetiske markører og relaterede fremgangsmåder og midler til detektion og behandling af ovariekræft Download PDFInfo
- Publication number
- DK3336197T3 DK3336197T3 DK16204822.7T DK16204822T DK3336197T3 DK 3336197 T3 DK3336197 T3 DK 3336197T3 DK 16204822 T DK16204822 T DK 16204822T DK 3336197 T3 DK3336197 T3 DK 3336197T3
- Authority
- DK
- Denmark
- Prior art keywords
- agents
- detection
- treatment
- ovarian cancer
- related methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Bioinformatics & Computational Biology (AREA)
- Databases & Information Systems (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Signal Processing (AREA)
- Artificial Intelligence (AREA)
- Evolutionary Computation (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Software Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16204822.7A EP3336197B1 (fr) | 2016-12-16 | 2016-12-16 | Marqueurs épigénétiques et procédés associés et moyens de détection et de gestion du cancer des ovaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3336197T3 true DK3336197T3 (da) | 2022-07-11 |
Family
ID=57609702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16204822.7T DK3336197T3 (da) | 2016-12-16 | 2016-12-16 | Epigenetiske markører og relaterede fremgangsmåder og midler til detektion og behandling af ovariekræft |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190323090A1 (fr) |
| EP (3) | EP3336197B1 (fr) |
| AU (2) | AU2017378196A1 (fr) |
| CA (2) | CA3047208A1 (fr) |
| DK (1) | DK3336197T3 (fr) |
| HU (1) | HUE059194T2 (fr) |
| IL (2) | IL267302A (fr) |
| PL (1) | PL3336197T3 (fr) |
| WO (2) | WO2018109212A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107532124B (zh) | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| EP3336197B1 (fr) | 2016-12-16 | 2022-04-06 | Eurofins Genomics Europe Sequencing GmbH | Marqueurs épigénétiques et procédés associés et moyens de détection et de gestion du cancer des ovaires |
| AU2018342449A1 (en) * | 2017-09-26 | 2020-04-16 | Juno Diagnostics, Inc. | Devices, systems and methods for biomarker analysis |
| TWI834642B (zh) | 2018-03-13 | 2024-03-11 | 美商格瑞爾有限責任公司 | 異常片段偵測及分類 |
| US12462935B2 (en) | 2018-03-30 | 2025-11-04 | Nucleix Ltd. | Deep learning-based methods, devices, and systems for prenatal testing |
| CA3102658A1 (fr) * | 2018-06-27 | 2020-01-02 | The Trustees Of Indiana University | Procedes d'analyse de l'adn dans l'urine |
| EP3867405A4 (fr) | 2018-10-17 | 2022-07-20 | The University of Queensland | Biomarqueur épigénétique et ses utilisations |
| WO2020132572A1 (fr) | 2018-12-21 | 2020-06-25 | Grail, Inc. | Source de déconvolution d'origine basée sur des fragments de méthylation dans des échantillons d'adn acellulaire |
| KR102185527B1 (ko) * | 2019-03-29 | 2020-12-02 | 가톨릭대학교 산학협력단 | 갑상선암 진단을 위한 갑상선암 특이적 dna 메틸화 바이오 마커의 검출 방법 및 조성물 |
| WO2021003485A1 (fr) * | 2019-07-03 | 2021-01-07 | The Board Of Trustees Of The Leland Stanford Junior University | Procédés d'évaluation de résultat clinique basé sur des probabilités mises à jour et traitements associés |
| US20220316013A1 (en) * | 2019-08-23 | 2022-10-06 | Agex Therapeutics, Inc. | Differentially-methylated regions of the genome useful as markers of embryo-adult transitions |
| EP4028586A4 (fr) * | 2019-09-13 | 2023-10-04 | University Health Network | Détection d'adn tumoral circulant à l'aide d'une capture hybride à double brin |
| CN112921086B (zh) * | 2019-12-06 | 2022-12-02 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | Circ-CRIM1作为卵巢癌诊断标志物及其应用 |
| CN112921085B (zh) * | 2019-12-06 | 2022-06-10 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | Circ-NOLC1作为卵巢癌诊断标志物及其应用 |
| US20230042332A1 (en) | 2019-12-24 | 2023-02-09 | Vib Vzw | Disease Detection in Liquid Biopsies |
| JP2024506854A (ja) * | 2021-01-29 | 2024-02-15 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 複数の種類のがんの有無の検出 |
| WO2022178108A1 (fr) * | 2021-02-17 | 2022-08-25 | University Of Southern California | Test de méthylation d'adn acellulaire |
| EP4170661A1 (fr) * | 2021-10-19 | 2023-04-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Analyse de profil de méthylation à l'aide d'un procédé de lissage |
| WO2023183812A2 (fr) * | 2022-03-21 | 2023-09-28 | Billion Toone, Inc. | Numération de molécules d'adn libre circulant méthylé pour une surveillance de traitement |
| KR20250148656A (ko) | 2023-02-17 | 2025-10-14 | 이지 바이오메드 씨오., 엘티디. | 췌장암의 조기 예측, 치료 반응, 재발 및 예후 모니터링을 위한 방법 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| AU2002212187A1 (en) | 2000-09-01 | 2002-03-13 | Epigenomics Ag | Diagnosis of illnesses or predisposition to certain illnesses |
| MXPA03001834A (es) | 2000-09-01 | 2003-08-01 | Epigenomics Ag | Metodo para determinar el grado de metilacion de determinadas citocinas en adn genomico en el contexto de secuencia 5'-cpg-3'. |
| WO2007019670A1 (fr) | 2005-07-01 | 2007-02-22 | Graham, Robert | Procede et acides nucleiques destines a ameliorer le traitement du cancer du sein |
| EP1862555A1 (fr) | 2006-05-29 | 2007-12-05 | Klinikum der Universität Regensburg | Moyens et procédés de diagnostic du cancer ou prédisposition correspondante |
| EP2304057B1 (fr) * | 2008-06-17 | 2014-09-17 | Signature Diagnostics AG | Methode pour detecter du cancer de l'ovaire |
| GB201102014D0 (en) | 2011-02-04 | 2011-03-23 | Ucl Business Plc | Method for predicting risk of developing cancer |
| US20140094380A1 (en) | 2011-04-04 | 2014-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methylation Biomarkers for Diagnosis of Prostate Cancer |
| ES2593959T3 (es) | 2011-04-19 | 2016-12-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Marcadores del cáncer de próstata |
| US20130041047A1 (en) | 2011-06-01 | 2013-02-14 | Aros Applied Biotechnology As | Urinary Methylation Markers for Bladder Cancer |
| US8885324B2 (en) | 2011-07-08 | 2014-11-11 | Kemet Electronics Corporation | Overvoltage protection component |
| US20130129668A1 (en) * | 2011-09-01 | 2013-05-23 | The Regents Of The University Of California | Diagnosis and treatment of arthritis using epigenetics |
| WO2015116837A1 (fr) * | 2014-01-30 | 2015-08-06 | The Regents Of The University Of California | Haplotypage de méthylation pour le diagnostic non invasif (monod) |
| EP3240912A4 (fr) * | 2014-12-31 | 2018-07-25 | Case Western Reserve University | Procédés et compositions de détection de néoplasies sophagiennes et/ou de métaplasies sophagiennes |
| US10961590B2 (en) * | 2015-09-17 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cancer detection methods |
| EP3336197B1 (fr) | 2016-12-16 | 2022-04-06 | Eurofins Genomics Europe Sequencing GmbH | Marqueurs épigénétiques et procédés associés et moyens de détection et de gestion du cancer des ovaires |
-
2016
- 2016-12-16 EP EP16204822.7A patent/EP3336197B1/fr active Active
- 2016-12-16 PL PL16204822.7T patent/PL3336197T3/pl unknown
- 2016-12-16 DK DK16204822.7T patent/DK3336197T3/da active
- 2016-12-16 HU HUE16204822A patent/HUE059194T2/hu unknown
-
2017
- 2017-12-15 US US16/469,946 patent/US20190323090A1/en not_active Abandoned
- 2017-12-15 US US16/469,963 patent/US11920200B2/en active Active
- 2017-12-15 EP EP17829175.3A patent/EP3555308B1/fr active Active
- 2017-12-15 AU AU2017378196A patent/AU2017378196A1/en not_active Abandoned
- 2017-12-15 AU AU2017375038A patent/AU2017375038A1/en not_active Abandoned
- 2017-12-15 EP EP17836012.9A patent/EP3555309B1/fr active Active
- 2017-12-15 CA CA3047208A patent/CA3047208A1/fr active Pending
- 2017-12-15 WO PCT/EP2017/083159 patent/WO2018109212A1/fr not_active Ceased
- 2017-12-15 WO PCT/EP2017/083170 patent/WO2018109217A1/fr not_active Ceased
- 2017-12-15 CA CA3047202A patent/CA3047202A1/fr active Pending
-
2019
- 2019-06-12 IL IL267302A patent/IL267302A/en unknown
- 2019-06-12 IL IL267300A patent/IL267300A/en unknown
-
2024
- 2024-01-22 US US18/418,913 patent/US12391995B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3336197B1 (fr) | 2022-04-06 |
| IL267302A (en) | 2019-08-29 |
| EP3555309C0 (fr) | 2023-09-13 |
| PL3336197T3 (pl) | 2022-08-08 |
| EP3555308B1 (fr) | 2023-12-13 |
| EP3555308C0 (fr) | 2023-12-13 |
| WO2018109217A1 (fr) | 2018-06-21 |
| US12391995B2 (en) | 2025-08-19 |
| CA3047208A1 (fr) | 2018-06-21 |
| AU2017378196A1 (en) | 2019-07-04 |
| WO2018109212A1 (fr) | 2018-06-21 |
| IL267300A (en) | 2019-08-29 |
| EP3555308A1 (fr) | 2019-10-23 |
| US20240200142A1 (en) | 2024-06-20 |
| CA3047202A1 (fr) | 2018-06-21 |
| EP3555309A1 (fr) | 2019-10-23 |
| US20190323090A1 (en) | 2019-10-24 |
| HUE059194T2 (hu) | 2022-10-28 |
| US20190330703A1 (en) | 2019-10-31 |
| EP3555309B1 (fr) | 2023-09-13 |
| AU2017375038A1 (en) | 2019-07-04 |
| EP3336197A1 (fr) | 2018-06-20 |
| US11920200B2 (en) | 2024-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3336197T3 (da) | Epigenetiske markører og relaterede fremgangsmåder og midler til detektion og behandling af ovariekræft | |
| IL272470A (en) | Methods and materials for assessing and treating cancer | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3888658T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
| DK3445767T3 (da) | Makrocykliske mcl1-inhibitorer til behandling af cancer | |
| DK3478286T3 (da) | Fremgangsmåder til behandling af ovariecancer | |
| EP3601993A4 (fr) | Dispositifs d'échantillonnage sous-marin et procédés associés | |
| DK3245225T3 (da) | Sammensætninger og fremgangsmåder til behandling og detektering af cancere | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3826667T3 (da) | Claudin6-antistoffer og fremgangsmåder til behandling af kræft | |
| DK4279084T3 (da) | Materialer og fremgangsmåder til behandling af duchennes muskeldystrofi | |
| DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3504242T3 (da) | Anti-ox40-antistoffer og anvendelse deraf | |
| DK3426777T3 (da) | Kombinationsvektorer og fremgangsmåder til behandling af cancer | |
| DK3159406T3 (da) | Kit eller indretning til påvisning af øsufagus-cancer og fremgangsmåde til påvisning | |
| DK3357000T3 (da) | Systemer og fremgangsmåder til cancerdetektering | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
| DK3988541T3 (da) | Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse | |
| DK3227237T3 (da) | Indretning og anvendelse deraf til uv-bearbejdning af fluider | |
| DK3122358T3 (da) | Kombinationer af fgfr- og cmet-hæmmere til cancerbehandling | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3493812T3 (da) | Kombinationer af imetelstat og venetoclax til behandling af akut myeloid leukæmi | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| DK3518932T3 (da) | Behandling af prostatacancer |